United States · 
Who invested in Axerion Therapeutics?
Axerion Therapeutics's investors include Connecticut Innovations.
2011
$750KSeed$400KVentureUnited States · Venture startup
Who invested in Axerion Therapeutics
2 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Follow Axerion Therapeutics and see its new rounds in your feed. Start following
Funding summaryUpdated 15 Nov 2026
$1.1Mraised across 2 rounds since 2010, from 2 sources
$750KSeed$400KVenture
- Latest round
- Venture, $400KOct 2011
- Biggest round
- $750KSeed · Apr 2010
- Investors
- 1
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Seed, $750K Apr 2010
- Biggest round
- $750K Seed · Apr 2010
- Between rounds
- 18 months from the last two
The rounds
- Oct 2011
- Apr 2010Seed$750K1 new
Reported by ctinnovations.comSEC filing: $758K sold, first sale Apr 2010
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Axerion Therapeutics
How much has Axerion Therapeutics raised?
Axerion Therapeutics has raised $1.1M across 2 rounds since 2010.
When did Axerion Therapeutics last raise?
Axerion Therapeutics's most recent round was a Venture of $400K in Oct 2011.
What was Axerion Therapeutics's biggest round?
Axerion Therapeutics's largest round on record is $750K (Seed), in Apr 2010.
Who backed Axerion Therapeutics first?
Axerion Therapeutics's first round on record, in Apr 2010, was backed by Connecticut Innovations.
What stage is Axerion Therapeutics at?
Axerion Therapeutics's latest named round is a Venture, in Oct 2011.
Where is Axerion Therapeutics based?
Axerion Therapeutics is based in the United States.
Companies like Axerion Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.